“…A similar profile was observed in the hippocampus, and microglia burden was reduced after EMP treatment in SP-free areas (close to plaques ([F (3,39) =2.21, p = 0.91]); far from plaques [F (7, 768) = 23.79, ╫╫ p < 0.01 vs. control, control-EMP, APP/ PS1, APP/PS1-EMP, and APP/PS1xdb/db-EMP, † † p < 0.01 vs. control, control-EMP, APP/PS1-EMP, and APP/PS1xdb/db-EMP, ♯♯ p < 0.01 vs. control and control-EMP]) (control n = 5, control-EMP n = 5, APP/PS1 n = 5, APP/PS1-EMP n = 4, db/db n = 6, db/db-EMP n = 4, APP/PS1xdb/db n = 4, APP/ PS1xdb/db-EMP n = 5). density after long-term administration, as previously described with other antidiabetic treatments [12,35,36]. Vascular disease has been closely associated to AD and T2D, and a synergistic effect has been reported when both pathologies coexist.…”